Expanding demand for oligonucleotide therapeutics and GMP-grade reagents drives steady global market expansionAustin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Phosphoramidite Market Size & Growth Analysis ...

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...

Q3 2025 Earnings Call Transcript November 7, 2025 Operator: Greetings, and welcome to the Codexis Third Quarter 2025 Earnings ...

Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., Nov.

NJ Bio, Inc., a premier contract research and clinical manufacturing service provider in Princeton, New Jersey has announced the asset purchase and full integration of the research services of L2P ...

Despite revenue declines, Codexis Inc (CDXS) focuses on innovation and strategic partnerships to drive long-term success.

Codexis (($CDXS)) has held its Q3 earnings call. Read on for the main highlights of the call. Codexis’s latest earnings call ...

Once the preserve of Asian beauty stores, you’ll now find Korean beauty products in almost every retailer, from Boots to ...

Here are the top medical news for the day Scientists uncover hidden blood biomarkers revealing higher diabetes risk in ...

Discover Codexis' Q3 2025 earnings highlights, strategic shift with Merck, and new leadership—positioning for growth in oligonucleotide manufacturing.

This study examines how evolutionary relaxation and functional change of INSL3 and RXFP2 relate to natural cryptorchidism in ...